Deborah Margaret Brown net worth and biography

Deborah Brown Biography and Net Worth

Director of Oncolytics Biotech

In addition to being a Management Consultant since 2014, Deborah Brown is currently a Managing Partner at Accelera Canada, a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company’s U.S. operations, and President and Managing Director of the company’s Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. Ms. Brown holds an MBA from University of Western Ontario’s Ivey School of Business, an Hons B.Sc. from the University of Guelph and completed the Merck executive development program at the University of Hong Kong, INSEAD and Northwestern University’s Kellogg School of Management.

What is Deborah Margaret Brown's net worth?: The estimated net worth of Deborah Margaret Brown is at least $94.10 thousand as of February 12th, 2026. Ms. Brown owns 109,851 shares of Oncolytics Biotech stock worth more than $94,098 as of August 28th. This net worth evaluation does not reflect any other investments that Ms. Brown may own. Learn More about Deborah Margaret Brown's net worth.
How do I contact Deborah Margaret Brown?: The corporate mailing address for Ms. Brown and other Oncolytics Biotech executives is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. Oncolytics Biotech can also be reached via phone at (403) 670-7377 and via email at [email protected]. Learn More on Deborah Margaret Brown's contact information.
Has Deborah Margaret Brown been buying or selling shares of Oncolytics Biotech?: Deborah Margaret Brown has not been actively trading shares of Oncolytics Biotech in the last ninety days. Most recently, on Thursday, February 12th, Deborah Margaret Brown bought 25,000 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $21,250.00. Following the completion of the transaction, the director now directly owns 109,851 shares of the company's stock, valued at $93,373.35. Learn More on Deborah Margaret Brown's trading history.
Who are Oncolytics Biotech's active insiders?: Oncolytics Biotech's insider roster includes Andrew Aromando (Chief Business Officer), Deborah Brown (Director), Allison Hagerman (Chief Technology Officer), and Bernd Seizinger (Director). Learn More on Oncolytics Biotech's active insiders.
Are insiders buying or selling shares of Oncolytics Biotech?: During the last year, Oncolytics Biotech insiders bought shares 14 times. They purchased a total of 404,282 shares worth more than $363,231.56. The most recent insider tranaction occured on March, 12th when CEO Jared Kelly bought 5,050 shares worth more than $4,848.00. Insiders at Oncolytics Biotech own 0.1% of the company. Learn More about insider trades at Oncolytics Biotech.
Information on this page was last updated on 3/12/2026.

Deborah Margaret Brown Insider Trading History at Oncolytics Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/12/2026	Buy	25,000	$0.85	$21,250.00	109,851

Deborah Margaret Brown Buying and Selling Activity at Oncolytics Biotech

Oncolytics Biotech Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: $0.86

$0.82

$0.86

50 Day Range

MA: $0.85

$0.75

$0.96

2 Week Range

Now: $0.86

$0.73

$1.51

Volume

671,581 shs

Average Volume

1,275,658 shs

Market Capitalization

$109.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13